These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 33719019)

  • 1. Review of Approaches for Increasing Ophthalmic Bioavailability for Eye Drop Formulations.
    Lanier OL; Manfre MG; Bailey C; Liu Z; Sparks Z; Kulkarni S; Chauhan A
    AAPS PharmSciTech; 2021 Mar; 22(3):107. PubMed ID: 33719019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanistic modeling of ophthalmic drug delivery to the anterior chamber by eye drops and contact lenses.
    Gause S; Hsu KH; Shafor C; Dixon P; Powell KC; Chauhan A
    Adv Colloid Interface Sci; 2016 Jul; 233():139-154. PubMed ID: 26318359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent advances in ocular drug delivery.
    Achouri D; Alhanout K; Piccerelle P; Andrieu V
    Drug Dev Ind Pharm; 2013 Nov; 39(11):1599-617. PubMed ID: 23153114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Bioavailability of drugs applied to the eye externally].
    Sieradzki E
    Klin Oczna; 1991 Jan; 93(1):34-6. PubMed ID: 2046287
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent Advances in Topical Ocular Drug Delivery.
    Yellepeddi VK; Palakurthi S
    J Ocul Pharmacol Ther; 2016 Mar; 32(2):67-82. PubMed ID: 26666398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ocular preparations: the formulation approach.
    Kaur IP; Kanwar M
    Drug Dev Ind Pharm; 2002 May; 28(5):473-93. PubMed ID: 12098838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Penetration enhancers and ocular bioadhesives: two new avenues for ophthalmic drug delivery.
    Kaur IP; Smitha R
    Drug Dev Ind Pharm; 2002 Apr; 28(4):353-69. PubMed ID: 12056529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Ways to improve ocular bioavailability for topical applications].
    Sirbat D; Marchal-Heussler L; Hoffman M; Maincent P
    J Fr Ophtalmol; 2000 May; 23(5):505-9; quiz 523. PubMed ID: 10844314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ophthalmic drug dosage forms: characterisation and research methods.
    Baranowski P; Karolewicz B; Gajda M; Pluta J
    ScientificWorldJournal; 2014; 2014():861904. PubMed ID: 24772038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel Ocular Drug Delivery Systems: An Update on Microemulsions.
    Üstündağ Okur N; Çağlar EŞ; Siafaka PI
    J Ocul Pharmacol Ther; 2020; 36(6):342-354. PubMed ID: 32255728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ocular drug metabolism of the bioactivating antioxidant N-acetylcarnosine for vision in ophthalmic prodrug and codrug design and delivery.
    Babizhayev MA
    Drug Dev Ind Pharm; 2008 Oct; 34(10):1071-89. PubMed ID: 18777243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Biological availability of ophthalmic drugs. 1. Increasing drug permeability in the cornea].
    Masteiková R; Chalupová Z; Savickiene N
    Ceska Slov Farm; 2004 Mar; 53(2):73-9. PubMed ID: 15095575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanotherapies for the treatment of ocular diseases.
    Reimondez-Troitiño S; Csaba N; Alonso MJ; de la Fuente M
    Eur J Pharm Biopharm; 2015 Sep; 95(Pt B):279-93. PubMed ID: 25725262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patent perspectives for corticosteroids based ophthalmic therapeutics.
    Suresh PK; Sah AK
    Recent Pat Drug Deliv Formul; 2014; 8(3):206-23. PubMed ID: 25020063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in ophthalmic drug delivery.
    Morrison PW; Khutoryanskiy VV
    Ther Deliv; 2014 Dec; 5(12):1297-315. PubMed ID: 25531930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent updates on ocular disease management with ophthalmic ointments.
    Bisen AC; Dubey A; Agrawal S; Biswas A; Rawat KS; Srivastava S; Bhatta RS
    Ther Deliv; 2024; 15(6):463-480. PubMed ID: 38888757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prodrugs and nanomicelles to overcome ocular barriers for drug penetration.
    Gote V; Ansong M; Pal D
    Expert Opin Drug Metab Toxicol; 2020 Oct; 16(10):885-906. PubMed ID: 32729364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug delivery to the anterior segment of the eye: A review of current and future treatment strategies.
    Mofidfar M; Abdi B; Ahadian S; Mostafavi E; Desai TA; Abbasi F; Sun Y; Manche EE; Ta CN; Flowers CW
    Int J Pharm; 2021 Sep; 607():120924. PubMed ID: 34324989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bioactivation antioxidant and transglycating properties of N-acetylcarnosine autoinduction prodrug of a dipeptide L-carnosine in mucoadhesive drug delivery eye-drop formulation: powerful eye health application technique and therapeutic platform.
    Babizhayev MA
    Drug Test Anal; 2012 Jun; 4(6):468-85. PubMed ID: 21416634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Transcorneal drug delivery: prospects for the use of liposomes].
    Aliautdin RN; Iezhitsa IN; Agarval R
    Vestn Oftalmol; 2014; 130(4):117-22. PubMed ID: 25306734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.